CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--ESP Equity Partners, LLC, a private investment company with operations in the U.S. and China today announced that it has continued its investment support for EKR Therapeutics by participating in EKR’s Series C financing round. EKR Therapeutics, led by Howard Weisman as Chairman and CEO, is a specialty pharmaceutical company focused on acquiring, developing, and commercializing proprietary therapeutics to enhance patient quality-of-life in the acute care setting. The Series C round successfully raised over $13 million for EKR through the private placement of preferred shares.
